Statins: The next step in adjuvant therapy for sepsis?

Intensive Care Medicine

Volumn 32, Issue 1, 2006, Pages 11-14

  Mekontso Dessap, Armand ^a   Brun Buisson, Christian ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Adjuvant therapy; HMG CoA; Sepsis; Statin

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE PHASE RESPONSE; ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BIOTRANSFORMATION; BLOOD VESSEL REACTIVITY; COHORT ANALYSIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG INHIBITION; EDITORIAL; HUMAN; INTENSIVE CARE UNIT; SEPSIS;

CHEMOTHERAPY, ADJUVANT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SEPSIS;

EID: 29844433612     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2860-5     Document Type: Editorial

References (25)

1. Kumana CR, Cheung BM, Lauder IJ (2003) Simvastatin reduced mortality and vascular events in high-risk patients. ACP J Club 138:2-3
2. The Scandinavian Simvastatin Survival Study (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383-9
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-57
4. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
5. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504
7. Chan KY, Boucher ES, Gandhi PJ, Silva MA (2004) HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61:1676-1681
8. Arnaud C,Mach F (2005) Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98:661-666
9. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188-4194
10. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, Egido J (2003) Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57:168-177
11. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21:1327-1332
12. Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841-1846
13. Krysiak R, Okopien B, Herman Z (2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63:1821-1854
14. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:575-585
15. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110:3349-3354
16. Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J (2004) Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21:271-275
17. Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136:143-149
18. Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595
19. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043-1046
20. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560-2565
21. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117-124
22. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880-885
23. Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352-1357
24. Fernandez R, De Pedro VJ, Artigas A (2005) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2005. DOI: 10.1007/s00134-005-2743-9
25. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2005) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2005. DOI: 10.1007/s00134-005-2859-y